Latest News

Sign up for our RSS Feed.
27 Apr 2015 NeurOp Announces Strategic Collaboration with Johnson & Johnson Innovation to St ... Read More
2 Oct 2014 NeurOp Receives Milestone Payment as Bristol-Myers Squibb Nominates NMDA Recepto ... Read More
Press Releases
123...
27 Apr 2015

NeurOp Announces Strategic Collaboration with Johnson & Johnson Innovation to Study Role of NMDA Receptors

ATLANTA, April 27, 2015 – NeurOp, Inc. today announced that it has entered into a research collaboration with Janssen Pharmaceuticals, Inc. to better understand how modulating the NMDA (N-methyl-D-a ... Read More
2 Oct 2014

NeurOp Receives Milestone Payment as Bristol-Myers Squibb Nominates NMDA Receptor Compound as Drug Development Candidate

ATLANTA, October 2, 2014 – NeurOp, Inc. today announced that Bristol-Myers Squibb has selected an NR2B-specific N-methyl-D-aspartate (NMDA) receptor modulator as a drug development candidate for tre ... Read More
29 Sep 2014

NeurOp Awarded NIH Grant for Alzheimer’s Disease Drug Research

ATLANTA, September 29, 2014 – NeurOp, Inc. announced today that the National Institutes of Health (NIH) has awarded it a grant to support research on new Alzheimer’s disease treatments. NeurOp is in ... Read More
11 Aug 2014

Lee H. Latimer Joins NeurOp to Manage Its Chemistry Operations

ATLANTA, August 11, 2014 – NeurOp, Inc. announces that Lee H. Latimer, Ph.D., has been appointed as its head of chemistry. He will oversee the company’s chemistry program to support its drug develop ... Read More
21 May 2014

NeurOp Selects NP10679 as Development Candidate for SAH

NeurOp, Inc. has selected NP10679 as a development candidate for the prevention of ischemic damage and its consequences in persons receiving surgical treatment for subarachnoid hemorrhage (SAH). NP1 ... Read More
123...